During the past decade, The Center for Hematology-Oncology conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 3 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The Center for Hematology-Oncology" #1 sponsor was "Telik" with 4 trials, followed by "Abbott" with 2 trials sponsored, "Agennix" with 2 trials sponsored, "Favrille" with 2 trials sponsored and "Sanofi" with 2 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The Center for Hematology-Oncology" #1 collaborator was "CIRION Central Laboratory" with 1 trials as a collaborator, "Dorevitch" with 1 trials as a collaborator, "ICON Clinical Research" with 1 trials as a collaborator, "National Cancer Institute (NCI)" with 1 trials as a collaborator and "ORION Clinical Services" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "The Center for Hematology-Oncology" are "Colorectal Cancer" (3 trials), "Prostate Cancer" (3 trials), "Lymphoma" (2 trials), "Ovarian Neoplasms" (2 trials) and "Adenocarcinoma of the Lung" (1 trials). Many other conditions were trialed in "The Center for Hematology-Oncology" in a lesser frequency.

Most popular intervention types in "The Center for Hematology-Oncology" are "Drug" (18 trials), "Biological" (5 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "oxaliplatin" (3 trials), "Carboplatin" (2 trials), "FOLFOX regimen" (2 trials), "Prednisone" (2 trials) and "autologous immunoglobulin idiotype-KLH conjugate vaccine" (2 trials). Other intervention names were less common.

The vast majority of trials in "The Center for Hematology-Oncology" are 14 trials for "All" genders, 3 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "The Center for Hematology-Oncology". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in The Center for Hematology-Oncology, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in The Center for Hematology-Oncology, 0 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".